<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6163">
  <stage>Registered</stage>
  <submitdate>21/10/2016</submitdate>
  <approvaldate>21/10/2016</approvaldate>
  <nctid>NCT02954341</nctid>
  <trial_identification>
    <studytitle>CardioMEMS HF System OUS Post Approval Study</studytitle>
    <scientifictitle>CardioMEMS HF System OUS Post Approval Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SJM-CIP-10147</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <healthcondition>Left-Sided Heart Failure</healthcondition>
    <healthcondition>Congestive Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - CardioMEMS HF System

Treatment: devices: CardioMEMS HF System


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Heart failure hospitalization rate</outcome>
      <timepoint>one year</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written informed consent obtained from subject

          -  &gt; 18 years of age

          -  Diagnosis of NYHA Class III Heart Failure

          -  At least 1 HF hospitalization within 12 months of Baseline visit

          -  Subjects with reduced LVEF heart failure should be receiving a beta blocker for 3
             months and an ACE-I or ARB for one month unless in the investigator's opinion, the
             subject is intolerant to beta blockers, ACE-I or ARB.

          -  Subjects willing and able to comply with the follow-up requirements of the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects with an active infection

          -  Subjects with history of recurrent (&gt; 1) pulmonary embolism or deep vein thrombosis

          -  Subjects who, in the Investigator's opinion, are unable to tolerate a right heart
             catheterization

          -  Subjects who have had a major cardiovascular event (e.g., myocardial infarction, open
             heart surgery, stroke, etc.) within 2 months of Baseline Visit

          -  Subjects with Cardiac Resynchronization Device (CRT) implanted &lt; 3 months prior to
             enrollment

          -  Subjects with a Glomerular Filtration Rate (GFR) &lt; 25 ml/min (obtained within 2 weeks
             of the baseline visit) who are non-responsive to diuretic therapy or who are on
             chronic renal dialysis

          -  Subjects with congenital heart disease or mechanical right heart valve(s)

          -  Subjects likely to undergo heart transplantation or VAD within 6 months of baseline
             visit

          -  Subjects with known coagulation disorders

          -  Subjects with a hypersensitivity or allergy to aspirin, and/or clopidogrel (not
             applicable for subjects taking anti-coagulation therapy or other approved
             anti-platelets therapy).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <postcode>4032 - Chermside</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this Post Approval Study (PAS) is to evaluate the use of the CardioMEMS HF
      System in patients with Class III Heart Failure in a commercial setting.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02954341</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Martin R Cowie, MD</name>
      <address>Royal Brompton &amp; Harefield NHS Foundation Trust</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Pascale Dardenne</name>
      <address />
      <phone />
      <fax />
      <email>pdardenne@sjm.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>